Clopidogrel/Acetylsalicylic acid Teva (clopidogrel;acetylsalicylic acid)
- Region
- 🇪🇺 EU
- Active substance
- clopidogrel;acetylsalicylic acid
- Company
- Teva Pharma B.V.
- Status
- Withdrawn
- Therapeutic area
- Acute Coronary Syndrome; Myocardial Infarction
- CHMP opinion
- Thu 26 Jun 2014
- EU approval
- Mon 01 Sep 2014
- Application
- EMEA/H/C/002272
- ATC
- B01AC30
- Official record
- www.ema.europa.eu
Indication
Clopidogrel/Acetylsalicylic acid Teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). Clopidogrel/Acetylsalicylic acid Teva is a fixed?dose combination medicinal product for continuation of therapy in: Non?ST segment elevation acute coronary syndrome (unstable angina or non?Q?wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention ST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 DuoPlavin Authorised · Sanofi Winthrop Industrie
- 🇪🇺 Clopidogrel / Acetylsalicylic acid Viatris (previously Clopidogrel / Acetylsalicylic acid Mylan) Authorised · Mylan Pharmaceuticals Limited
- 🇪🇺 Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover) Authorised · Sanofi-Aventis Groupe
- 🇪🇺 DuoCover Application withdrawn · Bristol Myers Squibb Pharma EEIG
- 🇪🇺 DuoPlavin Application withdrawn · Sanofi Pharma Bristol-Myers Squibb
Follow Clopidogrel/Acetylsalicylic acid Teva
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.